Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta

被引：5

作者：

Gibbs, E. ^{[1
]}

Tremlett, H. ^{[1
]}

Ball, N. ^{[2
]}

Hashimoto, S. ^{[1
]}

机构：

[1] Univ British Columbia, Fac Med, Dept Med, Div Neurol, Vancouver, BC V6T 2B5, Canada

[2] Univ British Columbia, Fac Med, Dept Pathol, Vancouver, BC V6T 2B5, Canada

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2008年 / 15卷 / 01期

关键词：

interferon beta; melanoma; multiple sclerosis; neutralizing antibodies;

D O I：

10.1111/j.1468-1331.2007.01989.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：E4 / E4

页数：1

共 7 条

[1]

CARMICHAEL VE, 1992, CAN J SURG, V35, P589

[2]

Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821

[3]

DUQUETTE P, 1995, NEUROLOGY, V45, P1277

[4]

Francis G, 2001, NEUROLOGY, V56, P1628

[5] Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis [J].

Kleinschmidt-DeMasters, BK ;

Tyler, KL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :369-374

[6] Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].

Panitch, H ;

Goodin, DS ;

Francis, G ;

Chang, P ;

Coyle, PK ;

O'Connor, P ;

Monaghan, E ;

Li, D ;

Weinshenker, B .

NEUROLOGY, 2002, 59 (10) :1496-1506

[7]

Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005

← 1 →